No association between polymorphisms in the glutamate transporter SLC1A2 and Parkinson's disease


  • Funding agencies: This study was financially supported by a grant from the Deutsche Forschungsgemeinschaft (KL1433/2-1) and the funds of the “Fakultätsübergreifende Forschungsförderung des Medizin-Ausschusses beider Medizinischer Fakultäten in Kiel und Lübeck” and the Hermann and Lilly Schilling Foundation. This work was supported, in part, by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services (project ZO1 AG000949-06). The authors thank the Institute of Clinical Molecular Biology in Kiel for providing genotyping as supported, in part, by the DFG Cluster of Excellence “Inflammation at Interfaces” and “Future Ocean.” We thank the technicians S. Greve and S. Arndt for technical support.

  • Full financial disclosures and author roles may be found in the online version of this article.

  • Drs. Appenzeller, Schulte, and Thier contributed equally to this work.

Correspondence to: Prof. Gregor Kuhlenbäumer, Department of Molecular Neurobiology, Institute of Experimental Medicine, Christian-Albrechts-University Kiel, Arnold-Heller Straße 3, Kiel 24105, Germany;

No abstract is available for this article.